

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

September 25th, 2023

[2023](#) | [News](#)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations:

- **“NMS-P945 an unique opportunity for enhanced efficacy versus MMAE and deruxtecan”**

NMS-P945 is a novel proprietary payload linker with DNA damaging mechanism and superior antiproliferative activity than MMAE and deruxtecan in chemoresistant models.

- **“A novel platform of diversified cytotoxins and targeted payloads to drive ADC innovation”**

NMS has generated a portfolio of novel and diversified payload linkers selected through a rigorous approach that leverages our proprietary chemical collection. This strategy is aimed at identifying optimal match with individual tumor types and targets and reaching a new generation ADCs with foreseen improved selectivity and antitumor efficacy even in chemoresistant settings.

NMS is keen to establish partnerships to leverage the value of its novel payload linker platform by conjugation with selected partner antibodies to fully exploit platform features.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) (NMS) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which originate from our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies. Our kinase platform has enabled us to out-license IP rights on approved innovative medicines such as encorafenib and entrectinib and currently includes preclinical to clinical stage products, which are being developed both in house and with partners, including four proprietary clinical assets in Phase I/II studies. Moreover, the development of our payload linker platform allows an extension of our pipeline with innovative payload linkers for next generation ADC production.

NMS combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with a global vision and a broad range of expertise in drug discovery and development. We collaborate with academia and clinical investigators as well as industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs.

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

A collaboration agreement with licensing option with Merck Healthcare KGaA for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293 signed as well as a four-target licensing agreement on proprietary payload-linker NMS-P945.

We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising pre-clinical assets.

About NMS Group

[NMS Group](#) S.p.A. (NMS Group) is the largest R&D company in Italy committed to the discovery and development of novel oncological therapies and through its three subsidiaries is the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product with more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing.

NMS Group's three subsidiaries are: NMS S.r.l., focused on discovery and clinical development of new drugs for oncology at Nerviano (Italy) and Boston (US) sites, Accelera S.r.l., one of the few Italian CROs capable of providing support through all phases of drug research and development, and NerPharMa S.r.l., a CDMO owing a wide and cutting edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products.

NMS Forward-Looking Statements

Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Actual results or developments may differ materially from those projected or implied in these forward-looking statements and historical results should not be considered as an indication of future performance. Factors that may cause such a difference include but are not limited to uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; ability to financially support product programs; reliance on third parties for development and manufacturing activities; changes in competitive products or in the standard of care; the risk of early termination of collaboration agreements;

These forward-looking statements are based on information available to, and expectations of NMS as of the date of this presentation. NMS disclaims any intention or obligation to update or revise any forward-looking statements.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it